Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

ARO-C3

Oligonucleotide (siRNA) · developed by ARROWHEAD PHARMACEUTICALS

Phase 1/2 Most advanced trial (none active)

ARWR Developer

1 Registered trials

What is ARO-C3?

ARO-C3 is a siRNA that reduces complement C3 production. It is being studied in C3 glomerulopathy and IgA nephropathy, kidney diseases involving complement-mediated injury.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type: Oligonucleotide (siRNA)
Therapy area: Renal & urology
Developer: ARROWHEAD PHARMACEUTICALS (ARWR)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 1/2

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT05083364	Phase 1/2	C3 Glomerulopathy	Completed	ARWR

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

C3 GlomerulopathyIgA Nephropathy

More from ARROWHEAD PHARMACEUTICALS

Plozasiran FDA approved ARC-521 Phase 1 ARC-AAT Phase 2 ARO-033 Phase 1 ARO-ALK7 Phase 1/2 ARO-ANG 3 Phase 2 ARO-APOC3 Phase 2 ARO-ATXN2 Phase 1 ARO-CFB Phase 1 ARO-DIMERPA Phase 1/2 ARO-ENaC Phase 1/2 ARO-HBV Phase 1/2

Follow ARWR, the company behind ARO-C3

See ARWR's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

ARWR catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z